Multi-parametric MRI-targeted biopsy compared to systematic TRUS biopsy for biopsy-naïve men at risk for prostate cancer: 2 year follow up data and economic analysis
Adverse pathology of prostate cancer after radical prostatectomy. Summary after 7 years and 1500 patients since introduction of mpMRI-guided biopsy in a real world setting
Can intraoperative nerve monitoring improve functional outcomes after unilateral- or non-nerve-sparing robot-assisted radical prostatectomy – a randomized clinical trial
Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS Trial
Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis
Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC)